Management of high-risk corneal grafts

Doug J. Coster, Keryn Williams

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Corneal transplantation is not invariably successful despite the anterior chamber of the eye being an immunologically privileged site. Inflammation erodes privilege. Other than by reducing inflammation through meticulous surgery, careful postoperative surveillance, and effective topical corticosteroids in the postoperative phase, there is little that a surgeon can do to improve the outlook for the majority of patients receiving corneal transplants. For patients at appreciable risk, HLA Class I matching may help where it is available. So too will systemic immunosuppression where it can be justified. Despite these measures, the results of corneal transplantation have not shown the improvement seen in solid organ transplantation over the last 30 years. New approaches applicable to corneal transplantation are required.

Original languageEnglish
Pages (from-to)996-1002
Number of pages7
JournalEye
Volume17
Issue number8
DOIs
Publication statusPublished - 1 Jan 2003
Externally publishedYes

Keywords

  • Antibody engineering
  • Gene therapy
  • HLA matching
  • High-risk corneal transplantation
  • Immunosuppression

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this